Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Novartis Meningococcal Group B Vaccine in Healthy Adults
NCT02305446Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2014
- Primary completion
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal meningitis, sponsored by Novartis. Started Dec 2014; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT02305446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305446.